PMID- 33488737
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210126
IS  - 1687-966X (Print)
IS  - 1687-9678 (Electronic)
VI  - 2020
DP  - 2020
TI  - Intravitreal Use of a Bone Marrow Mononuclear Fraction (BMMF) Containing CD34+ 
      Cells in Patients with Stargardt Type Macular Dystrophy.
PG  - 8828256
LID - 10.1155/2020/8828256 [doi]
LID - 8828256
AB  - To assess the therapeutic potential and the safety of intravitreous use of a bone 
      marrow mononuclear fraction (BMMF) containing CD34+ cells in patients with 
      Stargardt type macular dystrophy. The study was conducted on 10 patients with 
      Stargardt dystrophy with worse eye visual acuity </= 20/125. A bone marrow aspirate 
      was obtained from all patients, and after processing in the cell therapy center 
      (CTC), 0.1 ml of the intravitreous BMMF suspension was injected into the eye with 
      worse visual acuity. A sham injection was performed in the contralateral eye. The 
      patients were evaluated at baseline and one, three, and six months after the 
      injection. All of them were submitted to measurement of best corrected visual 
      acuity (BCVA), microperimetry, multifocal electroretinography (mfERG) and full 
      field electroretinography (ffERG), autofluorescence (AF), and optical coherence 
      tomography (OCT). Fluorescein angiography was also performed before and six 
      months after the injection. All patients completed the six-month period of 
      evaluation. Mean visual acuity of the treated eye was 1.1 logMAR (20/250) before 
      intravitreous (IV) injection, 0.96 logMAR (20/200+2) one month after injection, 
      and 0.92 logMAR (20/160-1) 3 months after injection. In the untreated eye, mean 
      VA was 1.0 logMAR (20/200) at baseline and 0.96 logMAR (20/200+2) and 0.94 logMAR 
      (20/160-2) one and three months after injection, respectively. In the treated 
      group, VA at baseline ranged from best acuity of 20/125-1 to worst acuity of 
      20/640+2, going through 20/100+2 and 20/400 during the first month. In the 
      untreated group, BCVA ranged from 20/100+2 to 20/400 at baseline and from 20/100 
      to 20/400 after one month. The results for the treated group differed 
      significantly at all follow-up times, whereas no significant difference was 
      observed in the untreated group. Regarding the mean sensitivity of 
      microperimetry, although there was improvement throughout all months, a 
      significant difference occurred only during the first month. In the untreated 
      eye, there was no significant difference in any analysis. Angiofluoresceinography 
      did not reveal neovessel formation or tumor growth. The remaining exams were used 
      in order to aid the diagnosis. The results indicate that the use of intravitreous 
      BMMF in patients with Stargardt dystrophy is safe and is associated with a 
      discrete improvement of BCVA and microperimetry in the treated eye compared to 
      the untreated one.
CI  - Copyright (c) 2020 Carina Costa Cotrim et al.
FAU - Cotrim, Carina Costa
AU  - Cotrim CC
AUID- ORCID: 0000-0001-6069-2502
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Ribeirao Preto Medical School, University of Sao Paulo, Brazil.
FAU - Vieira Messias, Andre M
AU  - Vieira Messias AM
AUID- ORCID: 0000-0002-5328-9608
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Ribeirao Preto Medical School, University of Sao Paulo, Brazil.
FAU - Jorge, Rodrigo
AU  - Jorge R
AUID- ORCID: 0000-0002-2652-0720
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Ribeirao Preto Medical School, University of Sao Paulo, Brazil.
FAU - Siqueira, Rubens Camargo
AU  - Siqueira RC
AUID- ORCID: 0000-0003-4563-1570
AD  - Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, 
      Ribeirao Preto Medical School, University of Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20201210
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC7787861
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
PMCR- 2020/12/10
CRDT- 2021/01/25 05:39
PHST- 2020/08/23 00:00 [received]
PHST- 2020/11/10 00:00 [revised]
PHST- 2020/11/18 00:00 [accepted]
PHST- 2021/01/25 05:39 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
PHST- 2020/12/10 00:00 [pmc-release]
AID - 10.1155/2020/8828256 [doi]
PST - epublish
SO  - Stem Cells Int. 2020 Dec 10;2020:8828256. doi: 10.1155/2020/8828256. eCollection 
      2020.